IRRAS AB publishes Interim Report for the period January to September 2022
Financial Runway Extended during Q3 as Revenue Growth Continues “Q3 2022 represented IRRAS’ 9th consecutive quarter of revenue growth, and the quarterly revenue of MSEK 11.0 represented 13% growth over Q2 2022 and 80% growth from the same period last year.” “With the company’s financial runway extended, increasing customer adoption and proving the clinical superiority of our products are now our top two priorities, and we are excited to continue to deliver such results in coming quarters.” Will Martin, CEO of IRRASThird quarter, July – September 2022 · Net revenue amounted to